{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:48:15Z","timestamp":1783763295288,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 AI143470"],"award-info":[{"award-number":["K23 AI143470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["212215"],"award-info":[{"award-number":["212215"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 HL166024"],"award-info":[{"award-number":["K24 HL166024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["WT108082AIA"],"award-info":[{"award-number":["WT108082AIA"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Emory Center for AIDS Research","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tenofovir\/lamivudine\/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on nonnucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective cohort study of PWH aged \u226518 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24 and 48 weeks later. The primary end point was viral suppression (&amp;lt;200\u2005copies\/mL) at 48 weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL &amp;gt;500\u2005copies\/mL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 500 participants (median age 47 years; 41% women). At 48 weeks after TLD transition, 94% of participants were in care with a VL &amp;lt;200\u2005copies\/mL (n = 469\/500); 2% (n = 11\/500) were lost from care or died; and only 2% (n = 9\/500) had a VL &amp;gt;500\u2005copies\/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9\/500) discontinued TLD due to adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04066036.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae260","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:02:36Z","timestamp":1715803356000},"page":"e622-e630","source":"Crossref","is-referenced-by-count":16,"title":["Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results"],"prefix":"10.1093","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8463-5430","authenticated-orcid":false,"given":"Suzanne M","family":"McCluskey","sequence":"first","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-2645","authenticated-orcid":false,"given":"Winnie R","family":"Muyindike","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Nanfuka","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-5732","authenticated-orcid":false,"given":"Daniel","family":"Omoding","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimusiima","family":"Komukama","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian T","family":"Barigye","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Kansiime","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Tumusiime","sequence":"additional","affiliation":[{"name":"Mbarara University of Science and Technology , Mbarara , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-9938","authenticated-orcid":false,"given":"Taing N","family":"Aung","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Stuckwisch","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9689-5413","authenticated-orcid":false,"given":"Bethany","family":"Hedt-Gauthier","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Biostatistics, Harvard T. H. Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-4689","authenticated-orcid":false,"given":"Vincent C","family":"Marconi","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine and Rollins School of Public Health, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahomed-Yunus S","family":"Moosa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of KwaZulu-Natal , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-244X","authenticated-orcid":false,"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, University College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Giandhari","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-710X","authenticated-orcid":false,"given":"Richard","family":"Lessells","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of KwaZulu-Natal , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-1808","authenticated-orcid":false,"given":"Ravindra K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Cambridge Institute of Therapeutic Immunology & Infectious Diseases, University of Cambridge , Cambridge , United Kingdom"},{"name":"Africa Health Research Institute , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-842X","authenticated-orcid":false,"given":"Mark J","family":"Siedner","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Africa Health Research Institute , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024092316164601800_jiae260-B1","author":"Clinton Health Access Initiative"},{"key":"2024092316164601800_jiae260-B2","author":"World Health Organization (WHO)"},{"key":"2024092316164601800_jiae260-B3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024092316164601800_jiae260-B4","author":"United States Agency for International Development, President's Emergency Plan For AIDS Relief"},{"key":"2024092316164601800_jiae260-B5","author":"US President's Emergency Plan for AIDS Relief (PEPFAR)."},{"key":"2024092316164601800_jiae260-B6","author":"The Republic of Uganda Ministry of Health"},{"key":"2024092316164601800_jiae260-B7","author":"The Republic of Uganda Ministry of Health"},{"key":"2024092316164601800_jiae260-B8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","article-title":"The impact of HIV-1 drug Escape on the global treatment landscape","volume":"26","author":"Collier","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2024092316164601800_jiae260-B9","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre","year":"2015","journal-title":"AIDS Rev"},{"key":"2024092316164601800_jiae260-B10","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024092316164601800_jiae260-B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2024092316164601800_jiae260-B12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7326\/M21-2229","article-title":"Resistance testing for management of HIV virologic failure in sub-Saharan Africa: an unblinded randomized controlled trial","volume":"174","author":"Siedner","year":"2021","journal-title":"Ann Intern Med"},{"key":"2024092316164601800_jiae260-B13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"The TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024092316164601800_jiae260-B14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"2024092316164601800_jiae260-B15","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"2024092316164601800_jiae260-B16","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1038\/s41467-020-19801-x","article-title":"Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase","volume":"11","author":"Siedner","year":"2020","journal-title":"Nat Commun"},{"key":"2024092316164601800_jiae260-B17","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024092316164601800_jiae260-B18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2024092316164601800_jiae260-B19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2024092316164601800_jiae260-B20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024092316164601800_jiae260-B21"},{"key":"2024092316164601800_jiae260-B22","author":"World Health Organization"},{"key":"2024092316164601800_jiae260-B23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2024092316164601800_jiae260-B24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz\u2013based regimen for the treatment of HIV-1","volume":"381","author":"The NAMSAL ANRS 12313 Study Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2024092316164601800_jiae260-B25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024092316164601800_jiae260-B26","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa2210005","article-title":"Second-line switch to dolutegravir for treatment of HIV infection","volume":"388","author":"Ombajo","year":"2023","journal-title":"N Engl J Med"},{"key":"2024092316164601800_jiae260-B27","first-page":"81","article-title":"D2EFT: dolutegravir and darunavir evaluation in adults failing first-line HIV therapy [CROI abstract 198].","volume":"31","author":"Matthews","year":"2023","journal-title":"Top Antivir Med"},{"key":"2024092316164601800_jiae260-B28","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/cid\/ciad023","article-title":"Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial","volume":"76","author":"Zhao","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024092316164601800_jiae260-B29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/QAI.0000000000003157","article-title":"Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks","volume":"92","author":"Keene","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024092316164601800_jiae260-B30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAI.0000000000003065","article-title":"Brief report: virologic impact of the dolutegravir transition: prospective results from the multinational African cohort study","volume":"91","author":"Esber","year":"2022","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"2024092316164601800_jiae260-B31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/ciab1006","article-title":"Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with human immunodeficiency virus treatment outcomes in sub-Saharan Africa","volume":"75","author":"Romo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024092316164601800_jiae260-B32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/dkad010","article-title":"Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey","volume":"78","author":"Kamori","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024092316164601800_jiae260-B33","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"2024092316164601800_jiae260-B34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/hiv.13189","article-title":"Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study)","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med"},{"key":"2024092316164601800_jiae260-B35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/v15010018","article-title":"Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-LINE ART in Cameroon: an evidence of a successful transition model","volume":"15","author":"Semengue","year":"2022","journal-title":"Viruses"},{"key":"2024092316164601800_jiae260-B36","author":"Hans L, Letsoalo E, Gaelejwe L, Magubane D, Steegen K.","year":"2023"},{"key":"2024092316164601800_jiae260-B37","author":"Namaynaja G, Watera C, Pals S, et al.","year":"2023"},{"key":"2024092316164601800_jiae260-B38","author":"United States Agency for International Development"},{"key":"2024092316164601800_jiae260-B39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae269","article-title":"Transitioning women to first-line preferred TLD regimen is lagging in sub-Saharan Africa","author":"Shah","journal-title":"Clin Infect Dis"},{"key":"2024092316164601800_jiae260-B40","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae260\/58503478\/jiae260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/3\/e622\/59248731\/jiae260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/3\/e622\/59248731\/jiae260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T16:17:11Z","timestamp":1727108231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/3\/e622\/7674855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae260","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,15]]},"published":{"date-parts":[[2024,5,16]]}}}